- Home
- OI vs RARE Comparison
OI vs RARE Comparison
Compare OI & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OI
- RARE
- Stock Information
- Founded
- OI 1903
- RARE 2010
- Country
- OI United States
- RARE United States
- Employees
- OI N/A
- RARE N/A
- Industry
- OI Containers/Packaging
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- OI Consumer Discretionary
- RARE Health Care
- Exchange
- OI Nasdaq
- RARE Nasdaq
- Market Cap
- OI 2.2B
- RARE 2.6B
- IPO Year
- OI N/A
- RARE 2014
- Fundamental
- Price
- OI $12.81
- RARE $32.03
- Analyst Decision
- OI Buy
- RARE Strong Buy
- Analyst Count
- OI 7
- RARE 14
- Target Price
- OI $16.71
- RARE $86.64
- AVG Volume (30 Days)
- OI 1.2M
- RARE 1.5M
- Earning Date
- OI 10-28-2025
- RARE 08-05-2025
- Dividend Yield
- OI N/A
- RARE N/A
- EPS Growth
- OI N/A
- RARE N/A
- EPS
- OI N/A
- RARE N/A
- Revenue
- OI $6,482,000,000.00
- RARE $610,159,000.00
- Revenue This Year
- OI $1.94
- RARE $19.72
- Revenue Next Year
- OI $1.07
- RARE $23.29
- P/E Ratio
- OI N/A
- RARE N/A
- Revenue Growth
- OI N/A
- RARE 26.77
- 52 Week Low
- OI $9.23
- RARE $25.81
- 52 Week High
- OI $16.04
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- OI 39.22
- RARE 65.03
- Support Level
- OI $12.78
- RARE $29.71
- Resistance Level
- OI $13.60
- RARE $30.61
- Average True Range (ATR)
- OI 0.34
- RARE 0.87
- MACD
- OI 0.01
- RARE 0.41
- Stochastic Oscillator
- OI 18.03
- RARE 95.60
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.